Mercado U, Díaz-Molina R

Language: Spanish
References: 11
Page: 334-337
PDF size: 273.12 Kb.

ABSTRACT

Background: B lymphocyte stimulator (BLyS/BAFF) is an endogenous protein that plays an important role in the differentiation and maduration of B lymphocytes. Enhanced levels of BLyS have been reported in lupus and other rheumatic diseases.
Methods: Serum samples from 92 lupus patients (94% females, median age 35.5 years) and 106 controls (50 healthy donors, 38 with rheumatoid arthritis, 18 with scleroderma) were analyzed for BLyS. The cutoff of BLyS › 1.98 ng/ml corresponds to the 95th percentile from the healthy donors. Antibodies against native DNA and disease activity also were evaluated in lupus patients. During follow up, BLyS levels in 32 patients showed heterogeneity.
Results: The median level of BLyS in 92 lupus patients was 1.9 ng/ mL (range 0.4-5.3), compared to 1.30, 1.35, and 1.35 ng/mL in healthy donors, rheumatoid arthritis, and scleroderma, respectively. Thirty-nine (42 %) out of 92 patients had elevated levels of BLyS (median 2.8 ng/mL). A moderate correlation between titers of anti-DNA antibody (r = 0.34) and Mex-SLEDAI (r = 0.45) was found. The monitoring of 32 patients showed persistently high levels, or normal or intermittent variations of BLyS.
Conclusion: The BLyS level is increased in some lupus patients. There was a moderate correlation with titers of anti-DNA antibody and disease activity. The monitoring of 32 patients showed heterogeneous levels of BLyS.

REFERENCES

1. Stohl W. Systemic lupus erythematosus: a BLySful, yet BAFFling, disorder. Arthritis Res Ther. 2003;5:136-138.

2. Marriette X, Roux S, Zhang J, Bengoufa D, Lavie F Zhou T, et al. The level of BLyS (BAFF) correlates with the titre of autoantibodies in human Sjogren´s syndrome. Ann Rheum Dis. 2003;62:168-171.

3. Mercado U. El estimulador de linfocitos B en lupus eritematoso sistémico. Rev Inst Mex Seguro Soc. 2012;50(4):349-50.

4. Zhang J, Roschke V, Baker KP, Wang Z, Alarcon GS, Fessler BJ, et al. Cutting edge: A role for B lymphocyte Stimulator in systemic lupus erythematosus. J Immunol. 2001;166:6-10.

5. Cheema GS, Roschke V, Hilbert DM, Stohl W. Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases. Arthritis Rheumatol. 2001;44:1313-9.

6. Elbirt D, Asher I, Mahlab-Guri K, Bezalel-Rosenberg S, Edelstein V, Sthoeger Z. BLyS levels in sera of patients with systemic lupus erythematosus: clinical and serological correlation. IMAJ 2014;16:491-6.

7. Petri M, Stohl W, Chath W, McCune WJ, Chevrier M, Ryel J, et al. Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus. Arthritis Rheumatol. 2008;58:2453-9.

8. Collins CE, Gavin AL, Migone TS, Hilbert DM, Nemazee D, Stohl W. B lymphocyte stimulator (BLyS) isoforms in systemic lupus erythematosus: disease activity correlates better with blood leukocyte BLyS mRNA levels than with plasma BLyS protein levels. Arthritis Res Ther. 2006;8(1):R6.

9. Van Vollenhoven RF. Systemic lupus erythematosus: which drugs and when? Int J Clin Rheumatol. 2014;9:385-94.

10. Guzman J, Cardiel MH, Arce-Salinas A, Sánchez- Guerrero J, Alarcón-Segovia D. Measurement of disease activity in systemic lupus erythematosus. Prospective validation of 3 clinical indices. J Rheumatol. 1992;19:1551-8.

11. Stohl W, Metyas S, Tan SM, Cheema GS, Oamar B, XU D, et al. B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus. Longitudinal observations. Arthritis Rheumatol. 2003; 48:3475-86.